5:31 PM
 | 
Nov 20, 2012
 |  BC Extra  |  Company News

Astellas seeking to expand U.S. approval for Tarceva

Astellas Pharma Inc. (Tokyo:4503) submitted an sNDA to FDA to expand the label of Tarceva erlotinib to include first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with...

Read the full 152 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >